Trump signed an executive order on April 18, 2026 to accelerate access to psychedelic drugs for patients with serious mental illness. The order directs the FDA to fast-track certain psychedelics with Breakthrough Therapy designations and establishes a pathway for eligible patients to access investigational psychedelic drugs like ibogaine, and provides $50 million in funding for states developing psychedelic treatment programs. Ibogaine is known to cause irregular heart rhythms and has been linked to more than 30 deaths in medical literature, though the order aims to enable objective scientific research.